Table of Contents
ISRN Pediatrics
Volume 2013 (2013), Article ID 140213, 6 pages
http://dx.doi.org/10.1155/2013/140213
Clinical Study

Heart Rate and Arterial Pressure Changes during Whole-Body Deep Hypothermia

1NICU, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Via Della Commenda 12, 20122 Milan, Italy
2NICU, Medical Surgical Feto-Neonatal Department, “A. Meyer” University Children’s Hospital, Viale G. Pieraccini, 24, 50139 Florence, Italy
3Neonatal Intensive Care Unit, “Carlo Poma” Hospital, Mantova, Italy

Received 31 January 2013; Accepted 18 March 2013

Academic Editors: A. Maheshwari and B. Vasarhelyi

Copyright © 2013 Giacomo Cavallaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Whole-body deep hypothermia (DH) could be a new therapeutic strategy for asphyxiated newborn. This retrospective study describes how DH modified the heart rate and arterial blood pressure if compared to mild hypothermia (MH). Fourteen in DH and 17 in MH were cooled within the first six hours of life and for the following 72 hours. Hypothermia criteria were gestational age weeks; birth weight  g; clinical signs of moderate/severe hypoxic-ischemic encephalopathy. Rewarming was obtained in the following 6–12 hours (0.5°C/h) after cooling. Heart rates were the same between the two groups; there was statistically significant difference at the beginning of hypothermia and during rewarming. Three babies in the DH group and 2 in the MH group showed HR < 80 bpm and QTc > 520 ms. Infant submitted to deep hypothermia had not bradycardia or Qtc elongation before cooling and after rewarming. Blood pressure was significantly lower in DH compared to MH during the cooling, and peculiar was the hypotension during rewarming in DH group. Conclusion. The deeper hypothermia is a safe and feasible, only if it is performed by a well-trained team. DH should only be associated with a clinical trial and prospective randomized trials to validate its use.